Prostate cancer is the most common malignancy among men found to be the second leading cause of male cancer-related mortality due to development of resistance against androgen deprivation therapy (ADT).
With the advancement in understanding of prostate cancer, numbers of agents have been emerged to target Androgen-Receptor (AR) signaling for the treatment of castration resistant prostate cancer (CRPC). Food and Drug Administration (FDA) has recently approved enzalutamide (XTANDI) for the treatment of CRPC. Androgen receptor promotes the prostate cancer progression after transformation. Androgen receptor signaling leads CRPC when cellular nucleus, binding to DNA and increasing pro cancer gene expression. In phase ІІІ clinical trial, enzalutamide shows that 160 mg once daily oral administration is well tolerated and significantly enhances overall survival in men with CRPC after chemotherapy, demonstrated by reduction in the serum prostate specific antigen (PSA) level and increased survival rate by 4.8 months.
Written by:
Dhingra R, Sharma T, Singh S, Sharma S, Tomar P, Malhotra M, Bhardwaj TR. Are you the author?
Department of Pharmaceutical Chemistry, Indo-Soviet Friendship (ISF) College of Pharmacy, Ferozepur Road, Moga-142 001, India.
Reference: Mini Rev Med Chem. 2013 May 15. Epub ahead of print.
PubMed Abstract
PMID: 23701654
